Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
| Revenue (TTM) | $85.53M |
| Gross Profit (TTM) | $49.97M |
| EBITDA | $7.82M |
| Operating Margin | -4.52% |
| Return on Equity | -78.60% |
| Return on Assets | 1.73% |
| Revenue/Share (TTM) | $19.20 |
| Book Value | $2.23 |
| Price-to-Book | 2.98 |
| Price-to-Sales (TTM) | 0.32 |
| EV/Revenue | 0.783 |
| EV/EBITDA | 46.09 |
| Quarterly Earnings Growth (YoY) | -80.30% |
| Quarterly Revenue Growth (YoY) | -4.70% |
| Shares Outstanding | $4.51M |
| Float | $3.53M |
| % Insiders | 7.65% |
| % Institutions | 45.05% |
Volatility is currently contracting